April 28, 2017 6:29pm

 

… Be damned if I know, although share pricing patterns send a message

But, it has to be received and acted upon …

 

… Is it about finding Nemo or …

Coming to terms with what investors need  

 

Pre-open indications: 3 hit and 4 miss by pennies

 

The truth is harsh, but reality is what it is!

 

I answer one question, in which company should investors commit and keep their money

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “there is a storm center moving toward the sector … Q1/17 financial results. The question will be who spent what and where is the result?”

  • Reiterating, “SELL the hype and BUY real facts.”

The NASDAQ ended down -0.2% with the DOW slipping -0.19% but, looked to close April with strong monthly gains.

  • One of my catalysts is game changing news – MiMedx (MDXG) closed Q1/17 at the top of its game!

Don’t expect much of ANYTHING as we step into the throes of financial reporting a.k.a. earnings and conference call season.

 

What analytics were there on Friday day and why it was important in today’s sector outcomes?

One answer … the economy is growing and the broader indexes had strong monthly gains while the cell therapy sector clipped the upside to dip and strip performance.

  • There is strong ANXIETY surrounding the promises that haven’t been fulfilled by the sector.

At the end of each day, what you think about where “our” universe is going – take a step back, throw salt over your shoulder and don’t step on cracks – and then remember NONE of it works … sustainably!

  • As the month ends … think about where the money is coming from to fund some continued development programs; past sources are getting TOO tapped and new money wants a clearer definition of forward catalysts and those who will be managing it – there is a giant slurping or gulping sound around this issue!

And that's a given!

 

The DOW closed down -0.19%% while the NASDAQ also closed down -0.02% … adding to what I said all week, emotional influence takes its toll, but investors need to be careful of the depreciating indexes!

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.9…

· Thursday traded near 10.77 as Wednesday and Tuesday traded near 10.8, Monday traded 10.9 – down -25.6% followed by last Friday trading near 14.67;

 

… The iShares Russell 2000 (IWM) indicated a negative -0.51% at the pre-open was and closed DOWN -1.34%;

… The iShares NASDAQ Biotechnology (IBB) indicated a positive +0.26% at the pre-open and closed UP +0.38%

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative  with an A/DL of 18/19 and 6 flats;

·         The mid-day stayed negative with an A/DL of 10/32 and 1 flat;

·         The close was negative with an A/DL of 16/26 and 1 flat;

 

… Decliners ranged from -0.11% <BLUE> to -3.90% <AST> in 26 equities;

… Gainers ranged from +2.53% <BSTG> to +11.32% <MDXG> in 16 equities;

 

 

Pre-open indications: 3 hit and 4 miss

·         AxoGen (AXGN) closed up +$0.05 – miss;

·         Biostage (BSTG) closed up +$0.01 – miss;

·         bluebird bio (BLUE) closed up +$0.03 – miss;

·         Cellectis SA (CLLS) closed down -$0.25 – hit;

·         MiMedx (MDXG) closed up +$1.29 – hit;

·         Mesoblast (MESO) closed down -$0.47 – hit;

·         Spark Therapeutics (ONCE) closed up +$0.13 – miss;

 

 

Percentage gainers:

·         MiMedx (MDXG) +11.32% after Thursday’s +3.73%,

·         Adverum (ADVM) +7.55% following Thursday’s -5.36% following Wednesday’s +5.66%,

·         International Stem Cell (ISCO) +4.48% after Thursday’s -4.29% following +7.36%,

·         Verastem (VSTM) +3.74%,

·         Biostage (BSTG) +$2.53% <+$0.01> after Thursday’s+6.35% <+$0.02>,

 

 

Percentage losers:

·         Asterias Biotherapeutics (NYSEMKT: AST) -3.90% after Thursday’s -4.94% after Wednesday’s +8% following Tuesday’s +10.29% after Monday’s+9.68%,

·         Mesoblast (MESO) -3.82%,

·         Cytori (CYTX) -3.74%,

·         Bellicum Pharma (BLCM) -3.26%,

·         Fibrocell (FCSC) -3.23%,

 

 

Dollar gainers:

·         MiMedx (MDXG) +$1.29 after Thursday’s +$0.30,

·         Adverum (ADVM) +$0.20,

·         Spark Therapeutics (ONCE) +$0.13 after Thursday’s +$0.60 after Wednesday’s +$0.32 following Tuesday’s +$2.08 after Monday’s +$2.34,

·         International Stem Cell (ISCO) +$0.08,

·         Verastem (VSTM) +$0.07,

 

 

Dollar losers:

·         Intrexon (XON) -$0.63,

·         Kite Pharma (KITE) -$0.56 after Thursday’s -$0.19 following Wednesday’s +$2.23 following Tuesday’s -$1.68,

·         Mesoblast (MESO) -$0.47,

·         Bellicum Pharma (BLCM) -$0.45,

·         Stemline (STML) -0.25 after Thursday’s-$0.40 after Wednesday’s +$0.35 following Tuesday’s +$0.35

 

 

Flats:

·         Northwest BIO (NWBO)

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.